In approximately 80% of breast cancer cases diagnosed in postmenopausal women, ER+ tumors proliferate in response to estrogen [38,39], making estrogen-modulating therapies like TAM a primary treatment option. The gene discussed is ESR1; the disease is breast carcinoma.